

Alexandar Tzankov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2922013/publications.pdf>

Version: 2024-02-01

454
papers

23,003
citations

17776

65
h-index

14386

132
g-index

492
all docs

492
docs citations

492
times ranked

36529
citing authors

#	ARTICLE	IF	CITATIONS
1	Interstitial Pulmonary Fibrosis and Extensive Dendriform Ossification with Persistent Viral Load: A Rare Presentation of Post-COVID-19 Condition in Need of Lung Transplantation. <i>Pathobiology</i> , 2023, 90, 138-146.	1.9	3
2	Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 403-413.	1.4	35
3	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
4	Increase in Chondroitin Sulfate and Decline in Arylsulfatase B May Contribute to Pathophysiology of COVID-19 Respiratory Failure. <i>Pathobiology</i> , 2022, 89, 81-91.	1.9	8
5	Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. <i>Leukemia</i> , 2022, 36, 1035-1047.	3.3	10
6	Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1583.	1.8	16
7	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	3.2	22
8	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	2.8	7
9	Genomic analysis of focal nodular hyperplasia with associated hepatocellular carcinoma unveils its malignant potential: a case report. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
10	Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Energy. <i>Cancer Research</i> , 2022, 82, 1234-1250.	0.4	8
11	IRF8 Is a Reliable Monoblast Marker for Acute Monocytic Leukemias, But Does Not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells. <i>American Journal of Surgical Pathology</i> , 2022, 46, 725-727.	2.1	3
12	SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. <i>Cancers</i> , 2022, 14, 916.	1.7	6
13	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. <i>Cancers</i> , 2022, 14, 1018.	1.7	7
14	Tumor Microenvironment in Acute Myeloid Leukemia: Adjusting Niches. <i>Frontiers in Immunology</i> , 2022, 13, 811144.	2.2	17
15	Extrafollicular proliferation of B-cells: Morphologic correlate to Spikevax-induced lymphadenopathy. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05398.	0.2	3
16	Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	21
17	Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19. <i>Pathobiology</i> , 2022, 89, 166-177.	1.9	4
18	Combined protein and nucleic acid imaging reveals virus-dependent B cell and macrophage immunosuppression of tissue microenvironments. <i>Immunity</i> , 2022, 55, 1118-1134.e8.	6.6	44

#	ARTICLE	IF	CITATIONS
19	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. <i>Nature Communications</i> , 2022, 13, .	5.8	28
20	SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy. <i>Haematologica</i> , 2021, 106, 619-621.	1.7	4
21	NUT midline carcinomas and their differentials by a single molecular profiling method: a new promising diagnostic strategy illustrated by a case report. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1007-1012.	1.4	11
22	Hunting coronavirus by transmission electron microscopy – A guide to SARS-CoV-2-associated ultrastructural pathology in COVID-19 tissues. <i>Histopathology</i> , 2021, 78, 358-370.	1.6	90
23	Cytokeratin expression in plasmablastic lymphoma – a possible diagnostic pitfall in the routine workup of tumours. <i>Histopathology</i> , 2021, 78, 831-837.	1.6	3
24	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	1.5	20
25	Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2021, 155, 239-266.	0.4	12
26	The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors. <i>Hematological Oncology</i> , 2021, 39, 3-10.	0.8	15
27	Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019. <i>Annals of Hematology</i> , 2021, 100, 117-133.	0.8	2
28	Placental Pathology Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion. <i>Pathobiology</i> , 2021, 88, 69-77.	1.9	101
29	Deciphering the genetic landscape of pulmonary lymphomas. <i>Modern Pathology</i> , 2021, 34, 371-379.	2.9	2
30	Haemophagocytic lymphohistiocytosis and liver failure-induced massive hyperferritinaemia in a male COVID-19 patient. <i>Swiss Medical Weekly</i> , 2021, 151, w20420.	0.8	5
31	Surgical Strategy Based on Radiological 3D Reconstruction in a Giant Metastatic Neuroendocrine Tumor of the Pancreas: A Case Report of an Interdisciplinary Approach. <i>Case Reports in Surgery</i> , 2021, 2021, 1-8.	0.2	2
32	Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	21
33	Ocular Pathology and Occasionally Detectable Intraocular Severe Acute Respiratory Syndrome Coronavirus-2 RNA in Five Fatal Coronavirus Disease-19 Cases. <i>Ophthalmic Research</i> , 2021, 64, 785-792.	1.0	35
34	SARS-CoV-2 entry factors are expressed in nasal, ocular, and oral tissues: implications for COVID-19 prophylaxes/therapeutics. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, AB2.	1.5	1
35	Genomic Landscape of Hodgkin Lymphoma. <i>Cancers</i> , 2021, 13, 682.	1.7	9
36	Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	66

#	ARTICLE	IF	CITATIONS
37	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. <i>Annals of Hematology</i> , 2021, 100, 1169-1179.	0.8	5
38	Detection of intact <i>Borrelia garinii</i> in a sural nerve biopsy. <i>Muscle and Nerve</i> , 2021, 63, E52-E55.	1.0	3
39	Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1078-1084.	0.7	1
40	Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 326-337.	1.3	27
41	Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study. <i>Case Reports in Oncology</i> , 2021, 14, 706-715.	0.3	15
42	Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3118-3118.	0.8	3
43	Histomorphological patterns of regional lymph nodes in COVID-19 lungs. <i>Der Pathologe</i> , 2021, 42, 89-97.	0.7	19
44	Case Report: Co-occurrence of Myocarditis and Thrombotic Microangiopathy Limited to the Heart in a COVID-19 Patient. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 695010.	1.1	6
45	The Role of Innate Immunity and Bioactive Lipid Mediators in COVID-19 and Influenza. <i>Frontiers in Physiology</i> , 2021, 12, 688946.	1.3	16
46	Neutrophil Extracellular Traps in Fatal COVID-19-Associated Lung Injury. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	32
47	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , 2021, 12, 5183.	5.8	26
48	SARS-CoV-2 infects human pancreatic Î² cells and elicits Î² cell impairment. <i>Cell Metabolism</i> , 2021, 33, 1565-1576.e5.	7.2	225
49	Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers. <i>Cell Reports Medicine</i> , 2021, 2, 100421.	3.3	11
50	Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. <i>EClinicalMedicine</i> , 2021, 41, 101139.	3.2	19
51	Neuropathology associated with SARS-CoV-2 infection. <i>Lancet, The</i> , 2021, 397, 276.	6.3	13
52	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1928365.	2.1	6
53	The pulmonary pathology of COVID-19. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 137-150.	1.4	123
54	Retrospective Post-mortem SARS-CoV-2 RT-PCR of Autopsies with COVID-19-Suggestive Pathology Supports the Absence of Lethal Community Spread in Basel, Switzerland, before February 2020. <i>Pathobiology</i> , 2021, 88, 95-105.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Investigations of Pathologists as a Key to Understanding Coronavirus Disease 2019. <i>Pathobiology</i> , 2021, 88, 11-14.	1.9	7
56	Flower lose, a cell fitness marker, predicts COVID-19 prognosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e13714.	3.3	4
57	Management of transthyretin amyloidosis. <i>Swiss Medical Weekly</i> , 2021, 151, w30053.	0.8	7
58	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. <i>Blood</i> , 2021, 138, 2395-2395.	0.6	1
59	Modeling the Cellular Origin of EVI1 + MLL-AF9-Driven Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 2210-2210.	0.6	0
60	Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies. <i>Cancers</i> , 2021, 13, 5605.	1.7	3
61	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. <i>Oncimmunology</i> , 2021, 10, 2003533.	2.1	18
62	Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histiocytic Response in Pulmonary Draining Lymph Nodes of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 763098.	2.2	12
63	Bone Marrow Infiltration of Angioimmunoblastic T-Cell Lymphoma: Identification and Prognostic Impact of Histologic Patterns and Diagnostic Application of Ancillary Phenotypic and Molecular Analyses. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 602-611.	1.2	5
64	The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review. <i>Pathobiology</i> , 2020, 87, 2-19.	1.9	20
65	Cluster Analysis According to Immunohistochemistry is a Robust Tool for Non-Small Cell Lung Cancer and Reveals a Distinct, Immune Signature-defined Subgroup. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 274-283.	0.6	5
66	Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. <i>Cell Metabolism</i> , 2020, 32, 829-843.e9.	7.2	122
67	Two distinct immunopathological profiles in autopsy lungs of COVID-19. <i>Nature Communications</i> , 2020, 11, 5086.	5.8	230
68	Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 2568-2583.	0.6	10
69	Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes. <i>Blood Advances</i> , 2020, 4, 5540-5546.	2.5	3
70	Delayed Diagnosis in Pulmonary Embolism: Frequency, Patient Characteristics, and Outcome. <i>Respiration</i> , 2020, 99, 589-597.	1.2	13
71	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	2.5	22
72	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1360-1369.	2.9	10

#	ARTICLE	IF	CITATIONS
73	SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report. <i>Lancet, The</i> , 2020, 396, 598-599.	6.3	41
74	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) – anatomic pathology perspective on current knowledge. <i>Diagnostic Pathology</i> , 2020, 15, 103.	0.9	126
75	The GM-CSF–IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	45
76	ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. <i>Nature Communications</i> , 2020, 11, 5453.	5.8	191
77	382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM). <i>Annals of Oncology</i> , 2020, 31, S404.	0.6	3
78	Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology. <i>Acta Neuropathologica</i> , 2020, 140, 583-586.	3.9	117
79	Lethal COVID-19: Radiologic-Pathologic Correlation of the Lungs. <i>Radiology: Cardiothoracic Imaging</i> , 2020, 2, e200406.	0.9	27
80	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	6.9	27
81	Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. <i>Histopathology</i> , 2020, 77, 198-209.	1.6	1,025
82	Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 120-128.	13.9	4,442
83	Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia. <i>Nature Communications</i> , 2020, 11, 2807.	5.8	18
84	Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial. <i>British Journal of Haematology</i> , 2020, 190, e258-e261.	1.2	9
85	Intraoperative frozen section consultation by remote whole-slide imaging analysis – validation and comparison to robotic remote microscopy. <i>Journal of Clinical Pathology</i> , 2020, 73, 350-352.	1.0	15
86	Unlocking the lockdown of science and demystifying COVID-19: how autopsies contribute to our understanding of a deadly pandemic. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 331-333.	1.4	19
87	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. <i>Hematological Oncology</i> , 2020, 38, 284-292.	0.8	23
88	Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. <i>British Journal of Haematology</i> , 2020, 189, 707-717.	1.2	13
89	Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera. <i>Journal of Hematopathology</i> , 2020, 13, 105-107.	0.2	4
90	Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best perceived in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1847-1850.	1.3	9

#	ARTICLE	IF	CITATIONS
91	Transforming activities of the <i>NUP98-KMT2A</i> fusion gene associated with myelodysplasia and acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 1857-1867.	1.7	7
92	3D virtual pathohistology of lung tissue from Covid-19 patients based on phase contrast X-ray tomography. <i>ELife</i> , 2020, 9, .	2.8	37
93	Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. <i>Swiss Medical Weekly</i> , 2020, 150, w20364.	0.8	10
94	Bone Marrow Changes Following Therapy and Immunosuppression. , 2020, , 314-339.		1
95	Infective, Granulomatous and Benign Histiocytic Disorders. , 2020, , 79-97.		0
96	Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 497-509.	1.4	8
97	High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 540-548.	1.3	49
98	Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group. <i>Pathobiology</i> , 2019, 86, 62-75.	1.9	3
99	MULTI-OMIC LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. <i>Hematological Oncology</i> , 2019, 37, 181-182.	0.8	0
100	Traumatic ulcerative granuloma with stromal eosinophilia—clinical case report, literature review, and differential diagnosis. <i>World Journal of Surgical Oncology</i> , 2019, 17, 184.	0.8	17
101	The <i>IL-6</i> signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. <i>EMBO Molecular Medicine</i> , 2019, 11, e10576.	3.3	38
102	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
103	How to resolve a clinical and molecular puzzle: concomitant monoclonal gammopathy of undetermined significance (MGUS) with neutrophilia and clonal hematopoiesis of indeterminate potential (CHIP). <i>Annals of Hematology</i> , 2019, 98, 2431-2432.	0.8	3
104	Lymphomas and Their Microenvironment: A Multifaceted Relationship. <i>Pathobiology</i> , 2019, 86, 225-236.	1.9	20
105	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	2.9	39
106	ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceded by clonally related lymphomatoid papulosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 763-767.	1.4	9
107	Our approach to bone marrow biopsies in cytopenia. <i>Pathology Research and Practice</i> , 2019, 215, 152447.	1.0	5
108	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , 2019, 104, e558-e561.	1.7	55

#	ARTICLE	IF	CITATIONS
109	Transformation of a splenic marginal zone lymphoma into classic Hodgkin lymphoma. <i>Journal of Clinical Pathology</i> , 2019, 72, 391-392.	1.0	4
110	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	1.6	106
111	Mushroom-shaped CAL2-positive tumor in the eye. <i>Blood</i> , 2019, 134, 2417-2417.	0.6	0
112	Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3020-3032.	2.5	19
113	PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 149-151.	0.8	1
114	Cyclosporine levels $\geq 195 \text{ \AA}^{\frac{1}{4}}\text{g/L}$ on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 971-977.	0.8	17
115	TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF- κ B mediated signaling in B-cells. <i>Haematologica</i> , 2019, 104, 766-777.	1.7	6
116	RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall. <i>Pathobiology</i> , 2019, 86, 162-166.	1.9	4
117	The sympathomimetic agonist mirabegron did not lower <i>JAK2</i> -V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. <i>Haematologica</i> , 2019, 104, 710-716.	1.7	29
118	Current lymphoma diagnostic standards: the pathologists'™ view. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 17-23.	0.3	1
119	T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights. <i>Leukemia and Lymphoma</i> , 2019, 60, 1320-1323.	0.6	3
120	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , 2019, 134, 5092-5092.	0.6	1
121	Transformation Mechanisms of the Nfia-ETO2 Fusion Gene Associated with Pediatric Pure Acute Erythroleukemia. <i>Blood</i> , 2019, 134, 532-532.	0.6	1
122	Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning. <i>Blood</i> , 2019, 134, 2891-2891.	0.6	1
123	Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1499-1499.	0.6	1
124	High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. <i>Leukemia</i> , 2018, 32, 2412-2426.	3.3	53
125	First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). <i>European Journal of Cancer</i> , 2018, 96, 6-16.	1.3	51
126	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. <i>Nature Communications</i> , 2018, 9, 1538.	5.8	49

#	ARTICLE	IF	CITATIONS
127	The tumor suppressive TGF- β /SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2235-2246.	0.6	41
128	A pattern-based approach to reactive lymphadenopathies. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 4-19.	1.0	21
129	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
130	Beneficial role of increased FOXP3 ⁺ regulatory T cells in acute myeloid leukaemia therapy response. <i>British Journal of Haematology</i> , 2018, 182, 581-583.	1.2	8
131	Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines. <i>Leukemia and Lymphoma</i> , 2018, 59, 1710-1716.	0.6	10
132	Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis. <i>Mucosal Immunology</i> , 2018, 11, 846-860.	2.7	9
133	Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 co-mutated myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response. <i>Leukemia and Lymphoma</i> , 2018, 59, 1994-1997.	0.6	5
134	CASTLE tumor of the parotid: First documented case, literature review, and genetic analysis of the cancer. <i>Head and Neck</i> , 2018, 40, E1-E4.	0.9	16
135	Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study. <i>Case Reports in Oncology</i> , 2018, 10, 876-884.	0.3	1
136	PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma. <i>Annals of Hematology</i> , 2018, 97, 355-357.	0.8	5
137	Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values. <i>Annals of Hematology</i> , 2018, 97, 2265-2266.	0.8	1
138	Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 54.	1.3	62
139	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	2.3	64
140	Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. <i>Annals of Hematology</i> , 2018, 97, 2117-2128.	0.8	26
141	Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues. <i>Laboratory Investigation</i> , 2018, 98, 1487-1499.	1.7	11
142	A Novel Inducible Mouse Model of MLL-ENL-driven Mixed-lineage Acute Leukemia. <i>HemaSphere</i> , 2018, 2, e51.	1.2	14
143	Aplastic Anemia. <i>Encyclopedia of Pathology</i> , 2018, , 1-8.	0.0	2
144	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 4912-4923.	3.9	214

#	ARTICLE	IF	CITATIONS
145	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	0.6	2
146	Diagnostic and prognostic impact of mucin 6 expression in non-small cell lung cancer. <i>Indian Journal of Pathology and Microbiology</i> , 2018, 61, 187.	0.1	6
147	Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF- κ B signalling instead of B-cell receptor signalling. <i>Hematological Oncology</i> , 2017, 35, 187-197.	0.8	12
148	Sharing of a PTPN11 mutation by myelodysplastic bone marrow and a mature plasmacytoid dendritic cell proliferation provides evidence for their common myelomonocytic origin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 469-473.	1.4	12
149	NF- κ B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. <i>Modern Pathology</i> , 2017, 30, 854-876.	2.9	15
150	Mutational landscape of B-cell post-transplant lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2017, 178, 48-56.	1.2	58
151	Hands-On Experience: Accreditation of Pathology Laboratories according to ISO 15189. <i>Pathobiology</i> , 2017, 84, 121-129.	1.9	12
152	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	1.9	39
153	MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 49-55.	1.4	25
154	Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 147, 292-300.	0.4	22
155	<i>Ex-vivo</i> assessment of drug response on breast cancer primary tissue with preserved microenvironments. <i>Oncotarget</i> , 2017, 6, e1331798.	2.1	35
156	Genetic background and evolution of relapses in aggressive B-cell lymphomas. <i>Haematologica</i> , 2017, 102, 1139-1149.	1.7	18
157	Is Rosai-Dorfman disease a reactive process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 545-547.	1.4	39
158	A More Accurate Approach to Amyloid Detection and Subtyping: Combining in situ Congo Red Staining and Immunohistochemistry. <i>Pathobiology</i> , 2017, 84, 49-55.	1.9	22
159	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. <i>Journal of Hematology and Oncology</i> , 2017, 10, 70.	6.9	66
160	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. <i>Blood</i> , 2017, 129, 333-346.	0.6	57
161	CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. <i>Cancer Research</i> , 2017, 77, 1097-1107.	0.4	59
162	Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. <i>Blood</i> , 2017, 129, 879-882.	0.6	44

#	ARTICLE	IF	CITATIONS
163	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017, 117, 1685-1688.	2.9	13
164	Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 609-619.	2.1	9
165	Response to the letter to the editor of Lambros et al.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 687-688.	1.4	0
166	Lymphadenectomy Specimens in a Large Retrospective Cohort of Pediatric Patients Reveal No in situ Lymphomas but a Broad Spectrum of Reactive Changes. <i>Pathobiology</i> , 2017, 84, 139-143.	1.9	2
167	WHOLE-EXOME SEQUENCING OF NODAL MARGINAL ZONE LYMPHOMAS IDENTIFIES RECURRENT MOLECULAR LESIONS IN GENES INVOLVED IN CHROMATIN REMODELLING AND NOTCH SIGNALLING. <i>Hematological Oncology</i> , 2017, 35, 149-149.	0.8	0
168	CHARACTERIZATION OF MEDIASTINAL LYMPHOMAS IN FEMALE SIBLINGS AND IDENTIFICATION OF <i>TIRAP</i> AS A NOVEL LYMPHOMA RISK GENE. <i>Hematological Oncology</i> , 2017, 35, 161-162.	0.8	0
169	Broken heart by T-prolymphocytic leukemia. <i>Blood</i> , 2017, 130, 691-691.	0.6	1
170	Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate. <i>Annals of Hematology</i> , 2017, 96, 681-682.	0.8	16
171	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. <i>Leukemia</i> , 2017, 31, 625-636.	3.3	47
172	Thymic Epithelial Tumors and Benign Thymic Lesions. , 2017, , 87-148.		1
173	Abstract 4833: Perfusion-based bioreactor culture of primary cancer tissue maintains tumor microenvironment complexity and allow in-vitro testing of immune blockade therapy. , 2017, , .		0
174	Fetal Inactivation of the Nuclear Interacting SET Domain Protein 1 Impairs Terminal Erythroid Maturation and Results in Acute Erythroleukemia in Mice. <i>Blood</i> , 2017, 130, 713-713.	0.6	2
175	Systemic eosinophilia with skin and pulmonary infiltrates in a patient with chronic lymphocytic leukemia: A case report. <i>Case Reports in Clinical Pathology</i> , 2016, 3, .	0.0	0
176	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	0.8	93
177	Commentary on "Randomized trial of thymectomy in myasthenia gravis". <i>Journal of Thoracic Disease</i> , 2016, 8, E1420-E1422.	0.6	3
178	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. <i>Oncotarget</i> , 2016, 7, 18036-18049.	0.8	26
179	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	0.6	59
180	Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. <i>Nature Communications</i> , 2016, 7, 12258.	5.8	76

#	ARTICLE	IF	CITATIONS
181	Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. <i>Human Pathology</i> , 2016, 54, 17-24.	1.1	136
182	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. <i>Leukemia</i> , 2016, 30, 2385-2395.	3.3	76
183	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	3.2	48
184	Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 463-471.	1.4	16
185	Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression. <i>Modern Pathology</i> , 2016, 29, 844-853.	2.9	7
186	CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 1780-1789.	0.6	33
187	The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. <i>Blood</i> , 2016, 127, 1438-1448.	0.6	59
188	Drug Reaction, Eosinophilia, and Systemic Symptoms (DRESS) syndrome associated with allopurinol leading to acute necrotizing eosinophilic myocarditis and death due to papillary muscle rupture. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1262-1264.	2.0	9
189	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
190	Histone deacetylase 1 plays a predominant pro-oncogenic role in $E\hat{1}/4$ -myc driven B cell lymphoma. <i>Scientific Reports</i> , 2016, 6, 37772.	1.6	10
191	Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung. <i>Pathobiology</i> , 2016, 83, 267-275.	1.9	21
192	MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. <i>Cancer Cell</i> , 2016, 30, 43-58.	7.7	176
193	Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder. <i>Leukemia and Lymphoma</i> , 2016, 57, 945-948.	0.6	5
194	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. <i>Leukemia</i> , 2016, 30, 361-372.	3.3	55
195	In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly. <i>Leukemia and Lymphoma</i> , 2016, 57, 39-44.	0.6	20
196	Effects of the Sympathomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14. <i>Blood</i> , 2016, 128, 3108-3108.	0.6	4
197	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	1.4	19
198	RelA NF- \hat{B} subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	1.4	29

#	ARTICLE	IF	CITATIONS
199	Abstract IA23: Leukemia development and the microenvironment. , 2016, , .		0
200	A Phase 1 study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS2594-TPS2594.	0.8	1
201	Abstract 615: Scaffold-based perfusion bioreactor system for in vitro maintenance of primary breast cancer tissue microenvironment suitable for personalized medicine. , 2016, , .		0
202	B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma. Blood, 2016, 128, 611-611.	0.6	0
203	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S228.	0.2	0
204	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S223.	0.2	0
205	ICSH guidelines for the standardization of bone marrow immunohistochemistry. International Journal of Laboratory Hematology, 2015, 37, 431-449.	0.7	31
206	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood, 2015, 125, 124-132.	0.6	79
207	Intracranial Interdigitating Dendritic Cell Sarcoma. Neurosurgery, 2015, 77, E979-E983.	0.6	13
208	Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. Journal of Hematology and Oncology, 2015, 8, 70.	6.9	28
209	Platelet-derived growth factor receptor $\hat{1}^2$ (PDGFR $\hat{1}^2$) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia. Histopathology, 2015, 67, 617-624.	1.6	5
210	Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 491-498.	0.6	30
211	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 5597-5614.	0.8	61
212	Array CGH-based analysis of post-transplant plasmacytic hyperplasia reveals "intact genomes" arguing against categorizing it as part of the post-transplant lymphoproliferative disease spectrum. Transplant International, 2015, 28, 120-122.	0.8	3
213	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF- $\hat{1}^B$ and JNK activation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E7230-8.	3.3	66
214	Primary Synovial Cell Sarcoma of the Kidney: Case Report and Review of the Literature. Case Reports in Oncology, 2015, 8, 128-132.	0.3	7
215	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. Lung Cancer, 2015, 87, 193-200.	0.9	115
216	When and how to test for C-MYC in aggressive B cell lymphomas. Journal of Hematopathology, 2015, 8, 13-20.	0.2	2

#	ARTICLE	IF	CITATIONS
217	Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 368-373.	1.0	25
218	DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2015, 212, 775-792.	4.2	59
219	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	7.7	378
220	Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 55-66.	1.4	12
221	LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. <i>Journal of Clinical Pathology</i> , 2015, 68, 473-478.	1.0	43
222	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	2.9	48
223	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	2.9	21
224	Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 255-263.	1.4	39
225	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	2.9	17
226	Numerical impairment of nestin+ bone marrow niches in acute GvHD after allogeneic hematopoietic stem cell transplantation for AML. <i>Bone Marrow Transplantation</i> , 2015, 50, 1453-1458.	1.3	12
227	Role of the Tumor Microenvironment in Breast Cancer. <i>Pathobiology</i> , 2015, 82, 142-152.	1.9	326
228	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 201-211.	1.5	85
229	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	0.8	72
230	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	0.8	35
231	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	0.8	33
232	Abstract P1-07-19: Effects of JAK pathway inhibition in pre-clinical models of breast cancer bone marrow metastases. , 2015, , .		0
233	Abstract 4136: Mutational analysis of paired primary and relapse diffuse large B-cell lymphoma. , 2015, , .		0
234	Myc-Directed Suppression of Autophagy Provides Therapeutic Vulnerabilities Targeting Amino Acid Homeostasis. <i>Blood</i> , 2015, 126, 2450-2450.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S75-9.	0.4	13
236	Characterization of the Inflammatory Infiltrate in <i>Streptococcus pneumoniae</i> ; Pneumonia in Young and Elderly Patients. <i>Pathobiology</i> , 2014, 81, 160-167.	1.9	24
237	Putative Stem Cell Markers in Non-Small-Cell Lung Cancer: A Clinicopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2014, 9, 41-49.	0.5	54
238	A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. <i>Leukemia</i> , 2014, 28, 1092-1102.	3.3	61
239	Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation. <i>Hematology</i> , 2014, 19, 280-285.	0.7	8
240	Phenotype profiling of primary testicular diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2014, 32, 72-81.	0.8	44
241	Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia. <i>Hematological Oncology</i> , 2014, 32, 47-51.	0.8	7
242	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S146-S147.	0.2	0
243	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S144-S145.	0.2	0
244	Clinical, Morphologic, Phenotypic, and Genetic Evidence of Cyclin D1-positive Diffuse Large B-cell Lymphomas With CYCLIN D1 Gene Rearrangements. <i>American Journal of Surgical Pathology</i> , 2014, 38, 719-727.	2.1	25
245	Correction: Prevalence and Clinical Implications of Epstein-Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 4974-4974.	3.2	2
246	Extracavitary primary effusion lymphoma: clinical, morphological, phenotypic and cytogenetic characterization using nuclei enrichment technique. <i>Histopathology</i> , 2014, 65, 693-706.	1.6	12
247	An Unexpected Cause of Diffuse Alveolar Hemorrhage in a Kidney Transplant Patient. <i>Respiration</i> , 2014, 87, 504-507.	1.2	3
248	Dkk3 levels in patients with myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2014, 133, 218-221.	0.8	2
249	Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21. <i>Human Pathology</i> , 2014, 45, 1003-1009.	1.1	12
250	Aplastic anemia: possible associations with lymphoproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 382-387.	0.7	14
251	Pharmacological and genomic profiling identifies NF- κ B-targeted treatment strategies for mantle cell lymphoma. <i>Nature Medicine</i> , 2014, 20, 87-92.	15.2	303
252	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	3.2	117

#	ARTICLE	IF	CITATIONS
253	Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. <i>Nature</i> , 2014, 512, 78-81.	13.7	375
254	CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. <i>Leukemia</i> , 2014, 28, 566-576.	3.3	32
255	Author's response to "Letter to the editor: unvalidated antibodies and misleading results". <i>Breast Cancer Research and Treatment</i> , 2014, 147, 459-462.	1.1	4
256	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	2.9	112
257	Follicular lymphoma transformation into histiocytic sarcoma: indications for a common neoplastic progenitor. <i>Leukemia</i> , 2014, 28, 1937-1940.	3.3	56
258	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	3.2	60
259	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	2.0	32
260	Deregulated cell death and lymphocyte homeostasis cause premature lethality in mice lacking the BH3-only proteins Bim and Bmf. <i>Blood</i> , 2014, 123, 2652-2662.	0.6	40
261	Unique Composite Hematolymphoid Tumor Consisting of a Pro-T Lymphoblastic Lymphoma and an Indeterminate Dendritic Cell Tumor: Evidence for Divergent Common Progenitor Cell Differentiation. <i>Pathobiology</i> , 2014, 81, 199-205.	1.9	23
262	Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction. <i>Haematologica</i> , 2014, 99, 1465-1471.	1.7	44
263	Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2562-2562.	0.8	1
264	JAK2 V617F-positive Primary Myelofibrosis with JAK2 Wild-type Monoblastic Transformation. <i>The Journal of Oncopathology</i> , 2014, 2, 47-51.	0.1	0
265	Abstract 5164: Lacking clonal relationship in 20% of relapsing diffuse large B-cell lymphomas. , 2014, , .		0
266	Conditional Expression of a Leukemogenic Fusion Oncogene in Murine Hematopoietic Stem Cells Results in Highly Invasive AML with Origin-Related Genetic Signatures of Prognostic Significance for the Human Disease. <i>Blood</i> , 2014, 124, 779-779.	0.6	0
267	Negligible Nuclear FOXP3 Expression in Breast Cancer Epithelial Cells Compared With FOXP3-Positive T Cells. <i>Clinical Breast Cancer</i> , 2013, 13, 264-270.	1.1	10
268	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
269	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
270	GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM. <i>Bone Marrow Transplantation</i> , 2013, 48, 715-721.	1.3	24

#	ARTICLE	IF	CITATIONS
271	CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells. <i>FASEB Journal</i> , 2013, 27, 3683-3701.	0.2	14
272	PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12420-12425.	3.3	233
273	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	1.7	142
274	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2013, 66, 956-961.	1.0	24
275	MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. <i>Leukemia</i> , 2013, 27, 1381-1390.	3.3	90
276	Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf. <i>Oncogene</i> , 2013, 32, 621-630.	2.6	15
277	NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1852-1859.	0.5	44
278	Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. <i>Blood</i> , 2013, 121, 1795-1804.	0.6	61
279	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	0.6	41
280	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 641-641.	0.6	3
281	A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2566-2566.	0.8	5
282	Potent Cooperation Between NUP98-NSD1 and FLT3-ITD In AML Induction. <i>Blood</i> , 2013, 122, 3797-3797.	0.6	0
283	A Novel Conditional Mouse Model For MLL-ENL Induced Acute Leukemia. <i>Blood</i> , 2013, 122, 1277-1277.	0.6	0
284	Sympathetic Neuropathy Of The Hematopoietic Stem Cell Niche Is Essential For Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 268-268.	0.6	0
285	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 363-363.	0.6	0
286	Tissue-Sparing Application of the Newly Proposed IASLC/ATS/ERS Classification of Adenocarcinoma of the Lung Shows Practical Diagnostic and Prognostic Impact. <i>American Journal of Clinical Pathology</i> , 2012, 137, 946-956.	0.4	52
287	Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. <i>Leukemia</i> , 2012, 26, 2421-2424.	3.3	100
288	PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2012, 107, 491-500.	2.9	60

#	ARTICLE	IF	CITATIONS
289	Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Medical Weekly, 2012, 142, w13511.	0.8	27
290	Prognostic and Predictive Value of Cell Cycle Deregulation in Non-Small-Cell Lung Cancer. Pathobiology, 2012, 79, 175-194.	1.9	25
291	Molecular and immunohistochemical characterization of B-cell lymphoma-2â€“negative follicular lymphomas. Human Pathology, 2012, 43, 405-412.	1.1	9
292	Large Granular Lymphocyte Expansion after Allogeneic Hematopoietic Stem Cell Transplant Is Associated with a Cytomegalovirus Reactivation and Shows an Indolent Outcome. Biology of Blood and Marrow Transplantation, 2012, 18, 1765-1770.	2.0	33
293	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	3.3	301
294	High prevalence of infections and autoimmunity in patients with thymoma. Human Immunology, 2012, 73, 287-290.	1.2	51
295	High transforming growth factor β^2 expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Human Pathology, 2012, 43, 339-349.	1.1	40
296	Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. Histopathology, 2012, 61, 18-25.	1.6	22
297	The elderly patient with surgically resected non-small cell lung cancer â€“ A distinct situation?. Experimental Gerontology, 2012, 47, 237-242.	1.2	24
298	Aplastic anemia in association with a lymphoproliferative neoplasm: Coincidence or causality?. Leukemia Research, 2012, 36, 250-251.	0.4	9
299	CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. Journal of Clinical Investigation, 2012, 122, 624-638.	3.9	84
300	Abstract 3795: BubR1 function is required for the antiproliferative activity of the novel microtubule-targeting drug BAL27862 (active moiety of the prodrug BAL101553). , 2012, , .		0
301	Cellular and Molecular Targets of MLL-AF9 in a Novel Conditional Mouse Model. Blood, 2012, 120, 1280-1280.	0.6	0
302	Prognostic molecular assays on the rise for non-small cell lung cancer. Journal of Thoracic Disease, 2012, 4, 217-8.	0.6	0
303	Clonal relationship of relapsing lymphoid neoplasms. Histology and Histopathology, 2012, 27, 1013-20.	0.5	2
304	PCM1â€“JAK2-fusion: a potential treatment target in myelodysplasticâ€“myeloproliferative and other hemato-lymphoid neoplasms. Expert Opinion on Therapeutic Targets, 2011, 15, 53-62.	1.5	22
305	Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2011, 105, 72-80.	1.8	14
306	Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component. American Journal of Surgical Pathology, 2011, 35, 177-189.	2.1	23

#	ARTICLE	IF	CITATIONS
307	Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. <i>Blood</i> , 2011, 117, 6227-6236.	0.6	165
308	A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1649-1657.	0.5	43
309	In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. <i>Annals of Hematology</i> , 2011, 90, 901-909.	0.8	29
310	Targetable molecular pathways in classical Hodgkin's lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 141-151.	1.9	3
311	Human Bone Marrow Hosts Polyfunctional Memory CD4+ and CD8+ T Cells with Close Contact to IL-15-Producing Cells. <i>Journal of Immunology</i> , 2011, 186, 6965-6971.	0.4	95
312	The Prognostic Impact of Sex on Surgically Resected Non-Small Cell Lung Cancer Depends on Clinicopathologic Characteristics. <i>American Journal of Clinical Pathology</i> , 2011, 135, 611-618.	0.4	28
313	Clonal Relationship of Classical Hodgkin Lymphoma and Its Recurrences. <i>Clinical Cancer Research</i> , 2011, 17, 5268-5274.	3.2	16
314	Minimal T-cell requirements for triggering haemophagocytosis associated with Epstein-Barr virus-driven B-cell proliferation: a clinical case study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1338-1339.	0.5	6
315	Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2011, 4, 106-114.	0.3	4
316	Absence of up-regulation for a proliferation-inducing ligand in Sjogren's sialadenitis lesions. <i>Rheumatology</i> , 2011, 50, 1211-1215.	0.9	10
317	The impact of aging on memory T cell phenotype and function in the human bone marrow. <i>Journal of Leukocyte Biology</i> , 2011, 91, 197-205.	1.5	77
318	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	0.6	3
319	Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. <i>Blood</i> , 2010, 115, 995-1005.	0.6	53
320	Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405 Operated Patients. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1325-1336.	0.5	41
321	Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. <i>Annals of Hematology</i> , 2010, 89, 663-669.	0.8	15
322	Consideration of exposure to pharmacological agents helps to avoid diagnostic pitfalls in bone marrow histopathology. <i>Memo - Magazine of European Medical Oncology</i> , 2010, 3, 132-135.	0.3	3
323	Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, Tj ETQq1 1 0.784314 rgBT / Over outcome in diffuse large B-cell lymphomas. <i>Experimental Hematology</i> , 2010, 38, 38-45.	0.2	34
324	Vav-1 expression correlates with NF- κ B activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines. <i>Hematological Oncology</i> , 2010, 28, 142-150.	0.8	11

#	ARTICLE	IF	CITATIONS
325	Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2010, 34, 585-593.	0.4	13
326	BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma. <i>Histopathology</i> , 2010, 56, 217-228.	1.6	47
327	FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at <i>3p14.1</i> . <i>Histopathology</i> , 2010, 57, 73-80.	1.6	39
328	Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas. <i>Disease Markers</i> , 2010, 29, 47-53.	0.6	87
329	Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies. <i>Journal of Oncology</i> , 2010, 2010, 1-13.	0.6	42
330	TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer. <i>PLoS ONE</i> , 2010, 5, e14282.	1.1	52
331	GATA1 mutations are not a hallmark of acute myeloid leukaemia with t(8;21). <i>Journal of Clinical Pathology</i> , 2010, 63, 471-472.	1.0	0
332	Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. <i>Genes and Development</i> , 2010, 24, 1602-1607.	2.7	95
333	Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 577-584.	1.5	78
334	Comment on "Cutting Edge: Depletion of Foxp3+ Cells Leads to Induction of Autoimmunity by Specific Ablation of Regulatory T Cells in Genetically Targeted Mice". <i>Journal of Immunology</i> , 2010, 184, 4051.1-4051.	0.4	7
335	Distribution of PD-1+ Lymphocytes in Reactive Lymphadenopathies. <i>Pathobiology</i> , 2010, 77, 24-27.	1.9	15
336	Refined Prognostic Role of CD68-Positive Tumor Macrophages in the Context of the Cellular Microenvironment of Classical Hodgkin Lymphoma. <i>Pathobiology</i> , 2010, 77, 301-308.	1.9	72
337	Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. <i>Human Pathology</i> , 2010, 41, 352-357.	1.1	115
338	Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?. <i>Human Pathology</i> , 2010, 41, 614-615.	1.1	0
339	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. <i>Leukemia and Lymphoma</i> , 2010, 51, 199-212.	0.6	88
340	Diagnostic and prognostic utility of PD-1 in B cell lymphomas. <i>Disease Markers</i> , 2010, 29, 47-53.	0.6	53
341	CD5 expression in de novo diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 2009, 20, 789-790.	0.6	7
342	Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. <i>Journal of Clinical Pathology</i> , 2009, 62, 754-756.	1.0	52

#	ARTICLE	IF	CITATIONS
343	New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2009, 62, 986-997.	1.0	23
344	BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. <i>Journal of Clinical Pathology</i> , 2009, 62, 903-907.	1.0	23
345	Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 455, 125-132.	1.4	66
346	Hodgkin lymphoma in Tyrol—a population-based study. <i>Annals of Hematology</i> , 2009, 88, 449-456.	0.8	5
347	Angiogenesis and vascular endothelial growth factor receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and <i>JAK2</i> mutational status. <i>British Journal of Haematology</i> , 2009, 146, 150-157.	1.2	76
348	Analysis of CD20 alone could be misleading in lineage determination of B-cell lymphomas: a case of CD20 negative diffuse large B-cell lymphoma in abdominal effusion. <i>Cytopathology</i> , 2009, 20, 273-274.	0.4	1
349	Recurrent numerical aberrations of <i>JAK2</i> and deregulation of the <i>JAK2</i> - <i>STAT</i> cascade in lymphomas. <i>Modern Pathology</i> , 2009, 22, 476-487.	2.9	79
350	Hypertrophic Scars and Keloids—A Review of Their Pathophysiology, Risk Factors, and Therapeutic Management. <i>Dermatologic Surgery</i> , 2009, 35, 171-181.	0.4	517
351	Prognostic importance of <i>BCL6</i> rearrangements in diffuse large B-cell lymphoma with respect to <i>Bcl6</i> protein levels and primary lymphoma site. <i>Human Pathology</i> , 2009, 40, 1055-1056.	1.1	9
352	Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. <i>Human Pathology</i> , 2009, 40, 1715-1722.	1.1	145
353	Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 1137-1145.	1.5	17
354	New <i>GATA1</i> mutation in codon 2 leads to the earliest known premature stop codon in transient myeloproliferative disorder. <i>Blood</i> , 2009, 114, 3717-3718.	0.6	5
355	Diagnostic Utility of the B-cell Lineage Markers CD20, CD79a, PAX5, and CD19 in Paraffin-embedded Tissues From Lymphoid Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 96-101.	0.6	37
356	Targetable oncogenic pathways in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 161-165.	0.3	0
357	Lack of protein expression of the simian virus 40 large T antigen in human lymphomas. <i>Journal of Medical Virology</i> , 2008, 80, 1112-1115.	2.5	1
358	Identification of the rare <i>EGFR</i> mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2008, 30, 1040-1044.	0.9	31
359	Cytokeratin expression in hematological neoplasms: A tissue microarray study on 866 lymphoma and leukemia cases. <i>Pathology Research and Practice</i> , 2008, 204, 569-573.	1.0	38
360	Differential diagnostic and functional role of the multi-marker phenotype <i>CDX2</i> / <i>CK20</i> / <i>CK7</i> in colorectal cancer stratified by mismatch repair status. <i>Modern Pathology</i> , 2008, 21, 1403-1412.	2.9	120

#	ARTICLE	IF	CITATIONS
361	Naturally occurring CD4 ⁺ CD25 ⁺ regulatory T cells modulate the haematopoietic potential of human stem cells <i>in vitro</i> . <i>British Journal of Haematology</i> , 2008, 142, 845-847.	1.2	2
362	Patterns of liver infiltration in lymphoproliferative disease. <i>Histopathology</i> , 2008, 53, 81-90.	1.6	48
363	Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases. <i>Experimental Hematology</i> , 2008, 36, 533-534.	0.2	5
364	Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. <i>Human Pathology</i> , 2008, 39, 1323-1330.	1.1	30
365	Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: Methodological aspects and applications. <i>Progress in Histochemistry and Cytochemistry</i> , 2008, 42, 203-252.	5.1	42
366	Large-Scale Analysis of Cell Cycle Regulators in Urothelial Bladder Cancer Identifies p16 and p27 as Potentially Useful Prognostic Markers. <i>Pathobiology</i> , 2008, 75, 25-33.	1.9	18
367	Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. <i>Journal of Clinical Pathology</i> , 2008, 61, 958-961.	1.0	27
368	Correlation of high numbers of intratumoral FOXP3 ⁺ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. <i>Haematologica</i> , 2008, 93, 193-200.	1.7	362
369	Twelve-year retrospective analysis of lung cancer – The TYROL Study: Daily routine in 1,424 patients (1995 – 2006). <i>Journal of Clinical Oncology</i> , 2008, 26, 19063-19063.	0.8	15
370	Solitary hydatid cyst in the tibia. <i>Annals of Tropical Medicine and Parasitology</i> , 2007, 101, 551-553.	1.6	2
371	Primary Ovarian Carcinoid Heart Disease Curatively Treated with a Two-Stage Procedure. <i>Thoracic and Cardiovascular Surgeon</i> , 2007, 55, 467-469.	0.4	5
372	Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. <i>Journal of Clinical Pathology</i> , 2007, 61, 31-35.	1.0	92
373	Deletion of C-MYC in the spectrum of transformed follicular lymphoma grade 3b. <i>Human Pathology</i> , 2007, 38, 191-192.	1.1	1
374	Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. <i>Human Pathology</i> , 2007, 38, 1057-1064.	1.1	37
375	EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. <i>Journal of Clinical Pathology</i> , 2007, 61, 307-310.	1.0	72
376	Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	1.0	4
377	The Role of Structural Extracellular Matrix Proteins in Urothelial Bladder Cancer (Review). <i>Biomarker Insights</i> , 2007, 2, BMI.S294.	1.0	33
378	Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. <i>Modern Pathology</i> , 2007, 20, 632-637.	2.9	28

#	ARTICLE	IF	CITATIONS
379	Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ transplant recipient. <i>Pediatric Transplantation</i> , 2007, 11, 547-551.	0.5	19
380	High-resolution ultrasound of peripheral neurogenic tumors. <i>European Radiology</i> , 2007, 17, 2880-2888.	2.3	118
381	Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 659-664.	1.4	20
382	Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas. <i>Biomarker Insights</i> , 2007, 2, 403-17.	1.0	0
383	Surgery for Foreign Body Reactions due to Injectable Fillers. <i>Dermatology</i> , 2006, 213, 300-304.	0.9	110
384	Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. <i>Leukemia and Lymphoma</i> , 2006, 47, 441-450.	0.6	23
385	Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra. <i>Leukemia and Lymphoma</i> , 2006, 47, 940-943.	0.6	4
386	Severe mesenteric and coronary vasculitis: a late and uncommon complication in a patient with chronic discoid lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2006, 35, 491-494.	0.6	2
387	Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2006, 42, 109-111.	1.3	153
388	Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL. <i>Medical Hypotheses</i> , 2006, 66, 577-579.	0.8	19
389	Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation—reply. <i>Human Pathology</i> , 2006, 37, 500-502.	1.1	6
390	Complete recovery after the removal of an ectopic testicle in a case of primary reninism and retroperitoneal hemangioma. <i>Asian Journal of Andrology</i> , 2006, 8, 247-250.	0.8	0
391	Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. <i>Modern Pathology</i> , 2006, 19, 291-298.	2.9	18
392	The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. <i>Leukemia</i> , 2006, 20, 1315-1316.	3.3	14
393	Marginal zone lymphoma of the lacrimal gland spreading to the lung and the bone marrow 11 years after first symptoms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 361-365.	1.4	2
394	Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer. <i>Cancer Detection and Prevention</i> , 2006, 30, 395-402.	2.1	37
395	Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 1321-1328.e2.	0.4	40
396	Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. <i>Cancer</i> , 2006, 107, 2801-2806.	2.0	19

#	ARTICLE	IF	CITATIONS
397	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. <i>International Journal of Cancer</i> , 2006, 118, 3161-3166.	2.3	44
398	Splenic Rupture, Beyond and Behind: A Histological, Morphometric and Follow-Up Study of 254 Cases. <i>Pathobiology</i> , 2006, 73, 280-287.	1.9	14
399	Diffuse Large B-Cell Lymphoma with Overexpression of Cyclin E Substantiates Poor Standard Treatment Response and Inferior Outcome. <i>Clinical Cancer Research</i> , 2006, 12, 2125-2132.	3.2	48
400	Angiogenesis in nodal B cell lymphomas: a high throughput study. <i>Journal of Clinical Pathology</i> , 2006, 60, 476-482.	1.0	56
401	Pathobiology of Classical Hodgkin Lymphoma. <i>Pathobiology</i> , 2006, 73, 107-125.	1.9	37
402	Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. <i>Journal of Clinical Pathology</i> , 2006, 60, 794-797.	1.0	24
403	Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. <i>Journal of Clinical Pathology</i> , 2006, 59, 48-55.	1.0	32
404	Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. <i>Journal of Experimental Medicine</i> , 2006, 203, 2939-2951.	4.2	209
405	Perivascular Treatment with Azathioprine Reduces Neointimal Hyperplasia in Experimental Vein Grafts. <i>Heart Surgery Forum</i> , 2006, 9, E515-E517.	0.2	8
406	Bilateral renal vein thrombosis in a twin newborn without known risk factors. <i>Clinical Nephrology</i> , 2006, 66, 135-139.	0.4	3
407	High Specificity of Combined TRAP and DBA.44 Expression for Hairy Cell Leukemia. <i>American Journal of Surgical Pathology</i> , 2005, 29, 474-478.	2.1	55
408	Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2005, 105, 4146-4146.	0.6	28
409	Incidental oral plasmablastic lymphoma with aberrant expression of CD4 in an elderly HIV-negative patient: how a gingival polyp can cause confusion. <i>Histopathology</i> , 2005, 46, 348-350.	1.6	27
410	Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2005, 153, 234-236.	1.4	20
411	Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine. <i>British Journal of Haematology</i> , 2005, 129, 199-205.	1.2	66
412	Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. <i>Modern Pathology</i> , 2005, 18, 90-96.	2.9	47
413	Rare expression of T-cell markers in classical Hodgkin's lymphoma. <i>Modern Pathology</i> , 2005, 18, 1542-1549.	2.9	83
414	Tissue microarray technology: principles, pitfalls and perspectives—lessons learned from hematological malignancies. <i>Experimental Gerontology</i> , 2005, 40, 737-744.	1.2	78

#	ARTICLE	IF	CITATIONS
415	Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. <i>European Journal of Haematology</i> , 2005, 75, 485-491.	1.1	101
416	Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. <i>BMC Cancer</i> , 2005, 5, 162.	1.1	33
417	Unilateral Breast Enlargement 5 Years After Reduction Mammoplasty. <i>Aesthetic Plastic Surgery</i> , 2005, 29, 404-406.	0.5	7
418	Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. <i>European Journal of Cardio-thoracic Surgery</i> , 2005, 27, 302-306.	0.6	31
419	Granulomatous reactions cause symptoms or clinically imitate treatment resistance in small lymphocytic lymphoma/chronic lymphocytic leukaemia more frequently than in other non-Hodgkin lymphomas. <i>Journal of Clinical Pathology</i> , 2005, 58, 815-819.	1.0	30
420	Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. <i>Immunology</i> , 2005, 114, 37-43.	2.0	228
421	Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. <i>Human Pathology</i> , 2005, 36, 1148-1151.	1.1	34
422	Complete or partial trisomy 3 in gastro-intestinal MALT lymphomas co-occurs with aberrations at 18q21 and correlates with advanced disease stage: A study on 25 cases. <i>World Journal of Gastroenterology</i> , 2005, 11, 7384.	1.4	17
423	Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 2005, 14, 1461-7.	1.2	13
424	Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas. <i>Journal of Clinical Pathology</i> , 2004, 57, 360-364.	1.0	19
425	Isolated bone marrow mycosis in a patient presenting with consumptive symptoms. <i>Journal of Clinical Pathology</i> , 2004, 57, 107-108.	1.0	2
426	Burkitt's Lymphoma of the Stomach: a Case Report with Molecular Cytogenetic Analysis. <i>Leukemia and Lymphoma</i> , 2004, 45, 1055-1059.	0.6	9
427	Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. <i>European Journal of Cardio-thoracic Surgery</i> , 2004, 25, 585-590.	0.6	31
428	Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. <i>Histopathology</i> , 2004, 45, 398-404.	1.6	18
429	Large-vessel arteritis and myelodysplastic syndrome: report of two cases. <i>European Journal of Haematology</i> , 2004, 73, 128-133.	1.1	31
430	Wegener's granulomatosis presenting with gross hematuria due to prostatitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 444, 92-94.	1.4	16
431	Mucinous non-neoplastic cyst of the pancreas accompanied by non-parasitic asymptomatic liver cysts. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 444, 482-484.	1.4	14
432	Molecular cytogenetic analysis of human spermatocytic seminomas. <i>Journal of Pathology</i> , 2004, 204, 277-281.	2.1	45

#	ARTICLE	IF	CITATIONS
433	Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. <i>Journal of Clinical Pathology</i> , 2004, 57, 927-931.	1.0	40
434	Subtotal tongue necrosis in delayed diagnosed giant-cell arteritis: A case report. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2004, 25, 438-441.	0.6	39
435	Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. <i>Annals of Thoracic Surgery</i> , 2004, 77, 1580-1585.	0.7	81
436	A new prognostic model (MPI) for patients with myelofibrosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 6621-6621.	0.8	0
437	A new prognostic model (MPI) for patients with myelofibrosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 6621-6621.	0.8	0
438	Detection of Apoptoses in Gastro-intestinal Graft-versus-host Disease and Cytomegalovirus Colitis by a Commercially Available Antibody Against Caspase-3. <i>Pathology Research and Practice</i> , 2003, 199, 337-340.	1.0	40
439	Congo Red-Positive Cardiac kappa-AL Amyloidosis in Plasmacytoma - Case Report and Review of the Literature. <i>Vienna Clinical Weekly</i> , 2003, 30, 29-32.	0.9	3
440	Atypical Carney's triad with coincidental clear cell renal carcinoma in an 84-year old patient's finding at autopsy. <i>Cancer Detection and Prevention</i> , 2003, 27, 256-258.	2.1	6
441	High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. <i>Journal of Pathology</i> , 2003, 199, 201-207.	2.1	59
442	Longer Failure-Free Survival Interval of Epstein-Barr Virus-Associated Classical Hodgkin's Lymphoma: A Single-Institution Study. <i>Modern Pathology</i> , 2003, 16, 566-573.	2.9	37
443	Expression of B-Cell Markers in Classical Hodgkin Lymphoma: A Tissue Microarray Analysis of 330 Cases. <i>Modern Pathology</i> , 2003, 16, 1141-1147.	2.9	116
444	Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. <i>Journal of Clinical Pathology</i> , 2003, 56, 747-752.	1.0	64
445	Glottis oedema and interstitial pulmonary disease as a result of extramedullary haemopoiesis in polycythaemia vera rubra causing asphyctic death. <i>Journal of Clinical Pathology</i> , 2003, 56, 79-79.	1.0	2
446	Retinoic Acid-Induced Golgi Apparatus Disruption in F2000 Fibroblasts: A Model for Enhanced Intracellular Retrograde Transport. <i>BMB Reports</i> , 2003, 36, 265-268.	1.1	1
447	Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. <i>Clinical Cancer Research</i> , 2003, 9, 1381-6.	3.2	42
448	Idiopathic Myelofibrosis with Nodal, Serosal and Parenchymatous Infiltration. <i>Acta Haematologica</i> , 2002, 107, 173-176.	0.7	8
449	Lipofuscinosis of the urinary bladder: a complication of chronic interstitial cystitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 200-201.	1.4	10
450	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. <i>Histopathology</i> , 2002, 41, 482-509.	1.6	75

#	ARTICLE	IF	CITATIONS
451	Primary gastric follicular lymphoma with parafollicular monocytoid B-cells and lymphoepithelial lesions, mimicking extranodal marginal zone lymphoma of MALT. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 614-617.	1.4	27
452	Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis. <i>Annals of Hematology</i> , 2001, 80, 423-425.	0.8	36
453	Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 0, , .	1.2	5
454	H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	1.4	0